it (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. In December of 2006 GSK announced a decision to discontinue the development of it for the treatment of HIV. The decision was based on issues regarding the formulation of the drug. it is a tyrosyl-based arylsulfonamide inhibitor of human immunodeficiency virus (HIV) protease. 
